Lercanidipine 10-20mg 30 tablets

Composition:
active ingredient: lercanidipine; 1 tablet contains lercanidipine hydrochloride 10mg or 20mg;
excipients: lactose monohydrate, microcrystalline cellulose sodium starch glycolate (type A); povidone, magnesium stearate; shell (for 10 mg tablets): Opadry II Yellow film coating mixture: HYPRO-melose (hydroxypropyl methylcellulose) lactose monohydrate, titanium dioxide (E 171) triacetin; iron oxide yellow (E 172).

Pharmacotherapeutic group:
Selective calcium antagonists with a predominant effect on the vessels. Derivatives of dihydropyridine. ATX code C08C A13.

Indications:
Mild or moderate essential hypertension.

Dosage and administration:
Mode of application Before using the drug, it is necessary to take into account that:
apply the drug preferably in the morning, at least 15 minutes before breakfast;
this medicine should not be taken with grapefruit juice.

The recommended dose is 10 mg orally once a day, taken no earlier than 15 minutes before a meal. Depending on the patient’s individual response to treatment, the dose may be increased to 20 mg. Dose titration should be gradual, since the maximum antihypertensive effect develops within 2 weeks of treatment.

Patients whose blood pressure will be adequately controlled on monotherapy with antihypertensive drugs may be offered to add Vanlerk to treatment regimens with β-blockers (atenolol), diuretics (hydrochlorothiazide) or ACE inhibitors (captopril or enalapril). Since the dose-response curve has a plateau between doses of 20-30 mg, it is unlikely that the effectiveness of the drug will increase with a high dose, while the risk of side effects may increase.

Elderly patients According to pharmacokinetic and clinical studies, lercanidipine can be used in elderly patients without special dose adjustments, but initiation of treatment in elderly patients should be under supervision.